TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05632302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nICP
Description: The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
Study: NCT04131062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Consent (iPad)
Description: Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
Study: NCT04280796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysical tasks
Description: All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysical tasks
Description: All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
Study: NCT04299035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector spinae plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector spinae plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector spinae plane block
Study: NCT01565681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1240
Description: infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion
Study: NCT03811314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic trinaing
Description: Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isotonic training
Description: Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
Study: NCT01332253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
Study: NCT03712787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilavonemab
Description: solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilavonemab
Description: solution for IV infusion
Study: NCT01740297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
Study: NCT02836405

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
Study: NCT05349786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
Study: NCT04195217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Art therapy
Description: When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist.
Study: NCT01481337

Intervention type: PROCEDURE
Intervention: Colonic polypectomy or endoscopic mucosal resection (EMR)
Description: Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
Study: NCT01698814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-4943A Ophthalmic Solution Vehicle
Description: Inactive ingredients used as placebo
Study: NCT03430960

Intervention type: OTHER
Group type: OTHER
Intervention: Phone Call
Description: Participants will be followed-up via phone call by Acute Pain Research Nurse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile App Survey
Description: Participants will be followed-up via mCare mobile app
Study: NCT01354717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brand Carac
Description: treatment of actinic keratosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic 0.5% 5-fluorouracil cream
Description: treatment of actinic keratosis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: treatment of actinic keratosis
Study: NCT02454478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT04066478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 75mg Dehydroepiandrosterone daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01115673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen Caplet - single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen Caplet - single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 0 mg Caplet - single dose
Study: NCT00965575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo. Taken 30 minutes prior to bedtime for four weeks.
Study: NCT02950480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zafirlukast
Description: Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (no intervention)
Description: Standard of Care (no intervention)
Study: NCT03342534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC-stimulator (Neuroconn, Germany)
Description: A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC-stimulator (Neuroconn, Germany)
Description: A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC-stimulator (Neuroconn, Germany)
Description: A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-stimulator (Neuroconn, Germany)
Description: A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
Study: NCT00432406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 5 mg/kg given at day 1, week 2, week 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 25 mg twice weekly
Study: NCT02791230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: Soft gel capsules administered once a day for 60 months
Study: NCT02474420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox administered per standard of care by the treating physician
Study: NCT02389621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study: NCT02638818

Intervention type: PROCEDURE
Intervention: minimally invasive pancreaticoduodenectomy
Description: Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.

Intervention type: PROCEDURE
Intervention: traditional pancreaticoduodenectomy
Description: Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
Study: NCT03728101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin, Dabigatran Etexilate
Description: The subjects receive dabigatran etexilate with and without simvastatin administration
Study: NCT04867980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
Study: NCT03373188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV
Study: NCT04867980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
Study: NCT02654054

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Elagolix
Description: Film-coated placebo tablets
Study: NCT01022840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine
Description: drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparison
Description: saline control
Study: NCT00654095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 20 mg once daily
Study: NCT04867980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
Study: NCT04192643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: 1 GR TRANEXAMİC ACİD İN 100 ML SALİNE SOLUTİON GİVEN İN 15 MİNUTES

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100 ML SALİNE SOLUTİON
Study: NCT02164045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT02436928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-501 High Dose vaccine
Description: Comparison of each dose of vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-501 High Dose vaccine with Adjuvant
Description: Comparison of each dose of vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-501 Low Dose vaccine
Description: Comparison of each dose of vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-501 Low Dose vaccine with Adjuvant
Description: Comparison of each dose of vaccine
Study: NCT01974973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT03373188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Undergo therapeutic conventional surgery
Study: NCT01167478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
Study: NCT04867980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
Study: NCT00375024

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patient Navigation
Description: Inclusion of Patient Navigator in treatment plan.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinic Staff
Description: Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
Study: NCT01589185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBSA301
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBSA301
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBSA301
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBSA301
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as a single intravenous infusion
Study: NCT01453296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444 25 μg; Novel dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444 25 μg; Novel dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo; Novel dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo; Novel dry powder inhaler
Study: NCT03841331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Placebo Tablets